Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteogenesis imperfecta.

Frank Rauch1, Francis H Glorieux

  • 1Genetics Unit, Shriners Hospital for Children and McGill University, 1529 Cedar Avenue, Montréal, Québec, Canada H3G 1A6.

Lancet (London, England)
|April 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Splice Variant in ERGIC1 Causes Arthrogryposis Multiplex Congenita-Characterization Using Urine-Derived Cells.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same author

Characterisation of Urine-Derived Cells for the Molecular Diagnosis of Rare Disorders.

International journal of molecular sciences·2026
Same author

Milestone Attainment in Young Children With Arthrogryposis Multiplex Congenita: Developmental Profile and Associated Factors.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same author

Expanding the Autosomal Recessive Hypophosphatemic Rickets Type I Carrier Phenotype and Adult Treatment with Burosumab.

Calcified tissue international·2026
Same author

Factors Associated With Functional Mobility in 256 Children With Arthrogryposis Multiplex Congenita: A Multicentric Cross-Sectional Study.

Archives of physical medicine and rehabilitation·2025
Same author

Psychometric properties of functional mobility outcome measures in children with arthrogryposis multiplex congenita.

Developmental medicine and child neurology·2025
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Osteogenesis imperfecta (OI) is a genetic bone fragility disorder. Bisphosphonate treatment offers an adjunct therapy for moderate to severe OI, though optimal regimens and long-term outcomes require further study.

Area of Science:

  • Genetics
  • Orthopedics
  • Pharmacology

Background:

  • Osteogenesis imperfecta (OI) is a genetic disorder characterized by bone fragility and low bone mass.
  • The disorder affects connective tissues and is typically caused by mutations in collagen type 1 genes.
  • Existing classifications of OI have been expanded from four to seven distinct types.

Purpose of the Study:

  • To provide an updated overview of Osteogenesis Imperfecta.
  • To discuss current therapeutic advancements and future research directions.

Main Methods:

  • Literature review and synthesis of existing research on Osteogenesis Imperfecta.
  • Analysis of current classification systems and genetic causes.
  • Evaluation of bisphosphonate therapy and emerging gene-based treatments.

Related Experiment Videos

Main Results:

  • The classification of OI has been refined to seven types.
  • Mutations in collagen type 1 genes are the primary cause, but not universally detected.
  • Bisphosphonate therapy represents a significant advance for moderate to severe OI cases.

Conclusions:

  • Bisphosphonate therapy is a valuable adjunct to standard care for Osteogenesis Imperfecta but is not a cure.
  • Optimal bisphosphonate treatment regimens and long-term outcomes remain to be determined.
  • Gene-based therapy for OI is currently in the preclinical research phase.